Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.1 USD | +0.59% | +8.05% | -34.53% |
Apr. 09 | Sector Update: Health Care Stocks Mixed in Late Afternoon Trading | MT |
Apr. 09 | Syros Gets Fast Track Label For Tamibarotene to Treat Acute Myeloid Leukemia; Shares Rise | MT |
Financials (USD)
Sales 2024 * | 2.8M | Sales 2025 * | 32.08M | Capitalization | 136M |
---|---|---|---|---|---|
Net income 2024 * | -125M | Net income 2025 * | -120M | EV / Sales 2024 * | 48.4 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 4.22 x |
P/E ratio 2024 * |
-1.38
x | P/E ratio 2025 * |
-1.53
x | Employees | 68 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 97.9% |
Latest transcript on Syros Pharmaceuticals, Inc.
1 day | +0.59% | ||
1 week | +8.05% | ||
Current month | -4.67% | ||
1 month | -20.31% | ||
3 months | -22.84% | ||
6 months | +117.95% | ||
Current year | -34.53% |
Managers | Title | Age | Since |
---|---|---|---|
Conley Chee
CEO | Chief Executive Officer | 54 | 21-09-26 |
Nancy Simonian
CEO | Chief Executive Officer | 63 | 12-10-31 |
Jason Haas
DFI | Director of Finance/CFO | 56 | 21-10-11 |
Members of the board | Title | Age | Since |
---|---|---|---|
Srini Akkaraju
BRD | Director/Board Member | 56 | 17-06-11 |
Tim Tyson
BRD | Director/Board Member | 71 | 22-09-15 |
Marsha Fanucci
BRD | Director/Board Member | 70 | 15-10-18 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-25 | 5.1 | +0.59% | 128,576 |
24-04-24 | 5.07 | -1.36% | 89,636 |
24-04-23 | 5.14 | +3.01% | 172,679 |
24-04-22 | 4.99 | +9.91% | 151,987 |
24-04-19 | 4.54 | -3.81% | 262,916 |
Delayed Quote Nasdaq, April 25, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-34.53% | 136M | |
+1.12% | 43.84B | |
+6.77% | 41.68B | |
+45.26% | 41.25B | |
-11.96% | 27.04B | |
+6.01% | 25.53B | |
-24.92% | 18.18B | |
-3.63% | 12.29B | |
+27.16% | 12.29B | |
+7.30% | 11.15B |
- Stock Market
- Equities
- SYRS Stock